255 related articles for article (PubMed ID: 29910042)
1. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.
Banham GD; Flint SM; Torpey N; Lyons PA; Shanahan DN; Gibson A; Watson CJE; O'Sullivan AM; Chadwick JA; Foster KE; Jones RB; Devey LR; Richards A; Erwig LP; Savage CO; Smith KGC; Henderson RB; Clatworthy MR
Lancet; 2018 Jun; 391(10140):2619-2630. PubMed ID: 29910042
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
3. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
Mohebbi N; Ritter A; Wiegand A; Graf N; Dahdal S; Sidler D; Arampatzis S; Hadaya K; Mueller TF; Wagner CA; Wüthrich RP
Lancet; 2023 Feb; 401(10376):557-567. PubMed ID: 36708734
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial.
Roemhild A; Otto NM; Moll G; Abou-El-Enein M; Kaiser D; Bold G; Schachtner T; Choi M; Oellinger R; Landwehr-Kenzel S; Juerchott K; Sawitzki B; Giesler C; Sefrin A; Beier C; Wagner DL; Schlickeiser S; Streitz M; Schmueck-Henneresse M; Amini L; Stervbo U; Babel N; Volk HD; Reinke P
BMJ; 2020 Oct; 371():m3734. PubMed ID: 33087345
[TBL] [Abstract][Full Text] [Related]
5. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
; Haynes R; Harden P; Judge P; Blackwell L; Emberson J; Landray MJ; Baigent C; Friend PJ
Lancet; 2014 Nov; 384(9955):1684-90. PubMed ID: 25078310
[TBL] [Abstract][Full Text] [Related]
8. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.
Cellier C; Bouma G; van Gils T; Khater S; Malamut G; Crespo L; Collin P; Green PHR; Crowe SE; Tsuji W; Butz E; Cerf-Bensussan N; Macintyre E; Parnes JR; Leon F; Hermine O; Mulder CJ;
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):960-970. PubMed ID: 31494097
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.
Hewett K; Sanders DB; Grove RA; Broderick CL; Rudo TJ; Bassiri A; Zvartau-Hind M; Bril V;
Neurology; 2018 Apr; 90(16):e1425-e1434. PubMed ID: 29661905
[TBL] [Abstract][Full Text] [Related]
12. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A; Muller P; Dore CJ; Ikeji F; Caverly E; Chowdhury K; Isenberg DA; Gordon C; Ehrenstein MR
BMJ Open; 2019 Dec; 9(12):e032569. PubMed ID: 31848169
[TBL] [Abstract][Full Text] [Related]
13. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
14. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
16. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
17. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
19. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
[TBL] [Abstract][Full Text] [Related]
20. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA
N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
